Abstract
Increased platelet reactivity has been implicated in the vascular complications of myeloproliferative diseases and diabetes mellitus. The mechanisms of platelet hyperresponsiveness have not been fully explained. Expression of CD36 or fatty acid translocase (FAT) and its role in arachidonic acid (AA) uptake by platelets were examined in subjects with myeloproliferative disorders(MPD), those with non-insulin-dependent diabetes mellitus (NIDDM), and in normal, healthy, age-matched controls. Surface expression of CD36 on platelet membranes was increased in MPD (10.94 ± 0.76 pmol/mg protein) compared with normal controls (6.94 ± 0.48 pmol/mg protein), p < 0.001. Total platelet content of CD36 was also significantly higher (32.1 ± 0.61 pmol/mg protein, p < 0.01) compared with those in sex and age matched normal controls (25.7 ± 1.09 pmol/mg protein). In contrast, platelet surface expression of CD36 in NIDDM (6.5 ± 0.56 pmol/mg protein) was not significantly different from those of normal controls despite higher total content of CD36 (32.8 ± 1.2, pmol/mg protein, p < 0 .01). Intact MPD platelets bound significantly more arachidonic acid (AA) (1.53 ± 0.16 nmol/mg protein, p < 0.05), compared with controls (1.12 ± 0.07 nmol/mg protein) or NIDDM subjects (1.16 ± 0.16 nmol/mg protein). The capacity of MPD platelet membranes to bind 14C-AA was also increased (1.72 ± 0.25 nmol/ protein, p < 0.05) compared with that of controls (1.62 ± 0.05 nmol/protein) and of NIDDM (1.22 ± 0.08 nmol/protein). This is consistent with higher surface expression of CD36 in MPD platelets. Membrane fatty acid analysis indicated that the % of AA in platelet phospholipids was significantly lower in MPD (3.15 ± 0.81%) compared with the controls (5.62 ± 1.7%, p < 0.05. The AA content of diabetic platelets (4.82 ± 1.1%) was not significantly different from normal controls. In summary, both total and surface expression of CD36 are increased in MPD, consistent with an enhanced capacity for uptake of AA by platelets. Increased expression of CD36 in platelets may play a role in the vaso-occlusive manifestations of MPD.
Similar content being viewed by others
References
Cortelazzo S, Viero P, Barbui T: Platelets activation in myeloproliferative disorders. Thromb Haemost 45: 211–213, 1981
Duttaroy AK: Insulin mediated processes in platelets, monocytes/ macrophages and erythrocytes: Effects of essential fatty acid metabolism. Prost Leuk Essntl Fatty Acids 51: 385–389, 1994
Wehmeier A, Sudhoff T, Meierkord F: Relation of platelet abnormalities to thrombosis and hemorrhage in chronic course of myeloproliferative disorders. Eur J Haematol 45: 191–197, 1997
Landolfi R, Ciabattoni G, Patrignani P, Castellana MAL, Pogliani E, Bizzi B, Patrono C: Increased thromboxane biosynthesis in patients with polycythemia vera: Evidence for aspirin-suppressible platelet activation in vivo. Blood 80: 1965–1971, 1992
Van Genderen PJJ, Prins FJ, Michiels JJ, Schror K: Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: As an antithrombotic agent. Br J Haematol 104: 438–441, 1999
Balduini CL, Bertolino G, Noris P, Piletta GC: Platelet aggregation in platelet rich plasma and whole blood in 120 patients with myeloproliferative disorders. Am J Clin Pathol 95: 82–86, 1991
Kaywin P, McDonough M, Insel PA, Shattil SJ: Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet alfa-adrenergic receptors. N Engl J Med 299: 505–509, 1978
Thibert V, Bellucci S, Cristofari M, Gluckman E, Legrand C: Increased platelet CD36 constitutes a common marker in myleoproliferative disorders. Br J Haematol 91: 618–624, 1995
Le Blanc K, Lindahl T, Rosendahl K, Samuelsson J: Impaired platelet binding of fibrinogen due to a lower number of GPIIb/IIIa receptors in polycythemia vera. Thromb Res 91: 287–295, 1998
Michelson AD, Wencel-Drake JD, Kestin AS, Barnard MR: Platelet activation results in a redistribution of glycoprotein IV (CD36). Arterioscler Thromb 14: 1193–1201, 1994
Ford I, Malik RA, Newrick PG, Preston FE, Ward JD, Greaves M: Thromb Haemost 68: 628–633, 1992
Phillips DR, Charo IF, Parise LV, Fitzerglad LA:The platelet membrane glycoprotein IIb-IIIa complex. Blood 71: 831–843, 1988
Duttaroy AK: Cellular uptake of long-chain fatty acids: Role of membrane-associated fatty acid-binding/transport proteins. Cell Mol Life Sci 57: 1360–1372, 2000
Ruggeri ZM: The platelet glycoprotein Ib-IX complex. Prog Hemost Thromb 10: 35–68, 1991
Silverstein RL, Asch AS, Nachman RL: Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion. J Clin Invest 84: 546–552, 1989
Greenwalt DE, Lipskey RH, Ockenhouse CF, Ikeda H, Tandon NN, Jamieson GA: Membrane glycoprotein CD36: A review of its role in adherence, signal transduction, and transfusion medicine. Blood 80: 1105–1115, 1992
Abumrad NA, El-Maghrabi MR, Amri EZ, Lopez E, Grimaldi PA: Cloning of a rat adipocyte membrane-protein implicated in binding or transport of long chain fatty acids that is induced during preadipocyte differentiation: Homology with human CD36. J Biol Chem 268: 17665–17668, 1993
Greenwalt DE, Scheck SH, Rhinehart T: Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet. J Clin Invest 96: 1382–1388, 1995
Duttaroy AK, Gordon MJ, Campbell FM, Crosbie L: Arachidonic acid uptake by human platelets is mediated by CD36. Platelets 7: 291–295, 1996
Ikeda H: Platelet membrane CD36. Hokkaido Igaku Zasshi 74: 99–104, 1999
Arita H, Nakano T, Hanasaki K: Thromboxane A2 - its generation and role in platelet activation. Prog Lipid Res 28: 273–301, 1989
Duttaroy AK, Ray TK, Sinha AK: Prostacyclin stimulation of the activation of blood coagulation factor X by platelets. Science 231: 385–388, 1986
Perez C, Ramiro JM, Campillo JE: Increased arachidonic acid uptake by platelets from insulin-dependent diabetics and diabetic rats. Diabet Res Clin Prac 7: 69–77, 1989
Mikhailidis DP, Jeremy JY, Barradas MA, Dandona P: Increased arachidonic acid incorporation into platelet phospholipids in type-2 (noninsulin-dependent) diabetes. Diabetologia 27: 242–248, 1984
Prisco D, Rogasi PG, Pannicia R, Abbate R, Gensini GF, Pinto S, Vanni D, Neri Seneri GG: Altered membrane fatty acid composition and increased thromboxane A2 generation in platelets from patients with diabetes. Prost Leuk Essen Fatty Acids 35: 15–33, 1989
Kieffer N, Bettaieb A, Legrand C, Coulombel L, Vainchenker W, Edelman L, Breton-Gorius J: Developmentally regulated expression of a 78 Kda erythoblast membrane glycoprotein immunologically related to the platelet thrombospondin receptor. Biochem J 262: 835–842, 1988
Beiso P, Pidard D, Fournier D, Dubernard V, Legrand C: Studies on the interaction of platelet glycoprotein IIb-IIIa and glycoprotein IV with fibrinogen and thrombospondin; a new immunochemical approach. Biochim Biophys Acta 1033: 7–12, 1990
Matsuno K, Diaz-Ricart M, Montgomery RR, Aster RH, Jamieson GA, Tandon NN: Inhibition of platelet adhesion to collagen by monoclonal anti-CD36 antibodies. Br J Haematol 92: 960–967, 1996
Diaz-Ricart M, Tandon NN, Gomezoritz G, Carretero M, Escolar G, Ordinas A, Jamieson GA: Antibodies to CD36 (GPIV) inhibit platelet-adhesion to sub-endothelial surfaces under flow conditions. Arterioscler Thromb Vasc Biol 16: 883–888, 1996
Tandon NN, Kralisz U, Jamieson GA: Identification of glycoprotein IV (CD36) as a primary receptor for platelet collagen adhesion. J Biol Chem 264: 7576–7583, 1989
Campbell FM, Bush P, Veerkamp JH, Duttaroy AK: Distribution of membrane associated and cytoplasmic fatty acid-binding proteins in human placenta. Placenta 19: 409–415, 1998
Campbell FM, Duttaroy AK: Plasma membrane fatty acid-binding protein (FABPpm) is exclusively located in the maternal facing membranes of the human placenta. FEBS Letts 375: 227–230, 1995
Campbell FM, Gordon MJ, Duttaroy AK: Plasma membrane fatty acid binding protein from human placenta: Identification and characterization. Biochem Biophys Res Commun 209: 1011–1017, 1995
Bradford MM: A rapid and sensitive method for the quantitation of microgramme quantitites of protein utilizing the principle of proteindye binding. Anal Biochem 72: 248–254, 1976
Legrand C, Dubernard V, Kieffer N, Nurden AT: Use of a monoclonal antibody to measure the surface expression of thrombospondin following platelet activation. Eur J Biochem. 171: 393–399, 1988
Legrand C, Pidart D, Beiso P, Tenza D, Edelman L: Interaction of monoclonal antibody to glycoprotein IV (CD36) with human platelets and its effect on platelet function. Platelets 2: 99–105, 1991
Duttaroy AK, Sinha AK: Purification and properties of prostaglandin E1/prostacyclin receptors of human blood platelets. J Biol Chem 262: 12685–12891, 1987
Yamamoto N, Ikeda H, Tandon NN, Herman J, Tomiyama Y, Mitani T, Sekiguchi S, Lipskey R, Kralisz U, Jamieson GA: A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: NAKa platelets lack detectable GPIV (CD36). Blood 76: 1698–1703, 1990
Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911–917, 1959
Crabtree J, Gordon MJ, Campbell FM, Duttaroy AK: Differential distribution and metabolism of arachidonic acid and docosahexaenoic acids by human placental cells. Mol Cell Biochem 185: 205–212, 1998
Major C, Wolf BA: Quantitation of the fatty acids composition of phosphatidic acid by capillary gas chromatography electron capture detection with picomole sensitivity. J Chromat B 658: 233–240, 1994
Kerkhoff C, Sorg C, Tandon NN, Nacker W: Interaction of S100A8/ S100A9-arachidonic acid complexes with the scavenger receptor CD36 may facilitate fatty acid uptake by endothelial cells. Biochem 40: 241–248, 2001
Volf I, Moeslinger T, Cooper J, Schmid W, Koller E: Human platelets exclusively bind oxidised low density lipoprotein showing no specificity for acetylated low density lipoprotein. FEBS Lett 449: 141–145, 1999
Mahfouz MM, Kummerow FA: Oxidised low-density lipoprotein (LDL) enhances thromboxane A2 synthesis by platelets, but lysolecithin as a product of LDL oxidation has an inhibitory effect. Prost Other Lipid Mediat 62: 183–200, 2000
Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Lia D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P: A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7: 161–171, 2001
Devraj S, Hugou I, Jialal I: α-Tocopherol decreases CD36 expression in human monocyte-derived macrophages. J Lipid Res 42: 521–527, 2001
Kalofoutis A, Lekakis J: Changes of platelet phospholipids in diabetes mellitus. Diabetologia 21: 540–543, 1981
Jones DB, Carter RD, Haitas B, Mann JI: Low phospholipid arachidonic acid values in diabetic platelets. Br Med J 286: 173–175, 1983
Nordy A, Rodset JM: Platelet phospholipids and their function in patients with juvenile diabetes and maturity onset diabetes. Diabetes 19: 698–702, 1970
Castaldi PA, Brendt MC, Booth W, Bull H, Greaves M: Evidence for a platelet membrane defect in the myeloproliferative syndromes. Thromb Res 27: 601–609, 1982
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Salah-Uddin, H., Gordon, M.J., Ford, I. et al. Surface expression of fatty acid translocase (FAT/CD36) on platelets in myeloproliferative disorders and non-insulin dependent diabetes mellitus: Effect on arachidonic acid uptake. Mol Cell Biochem 239, 203–211 (2002). https://doi.org/10.1023/A:1020583630536
Issue Date:
DOI: https://doi.org/10.1023/A:1020583630536